Alkermes plc (NASDAQ:ALKS) is one of the most promising mid-cap healthcare stocks under $50. At the close of play on December 19, the consensus ratings remain bullish for Alkermes plc (NASDAQ:ALKS). The stock has been covered by 15 analysts, of which 11 assigned it Buy ratings and the remaining 4 were Holds. As per analyst estimates, the forecasted median 1-year price target for the stock is$46.17 a share, resulting in 62.3% upside potential at the prevailing prices. Likoper/Shutterstock.com On Decemb ...